Digitoxin

Gefahreninformationscode (GHS)

• Bildanzeige (GHS)

  

• Alarmwort

  Achtung

• Gefahrenhinweise

  H300：Lebensgefahr bei Verschlucken.

  H331：Giftig bei Einatmen.

  H373：Kann die Organe schädigen bei längerer oder wiederholter Exposition.

• Sicherheit

  P260：Dampf/Aerosol/Nebel nicht einatmen.

  P264：Nach Gebrauch gründlich waschen.

  P264：Nach Gebrauch gründlich waschen.

  P270：Bei Gebrauch nicht essen, trinken oder rauchen.

  P301+P310：BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen.

  P314：Bei Unwohlsein ärztlichen Rat einholen / ärztliche Hilfe hinzuziehen.

Digitoxin Chemische Eigenschaften,Einsatz,Produktion Methoden

• R-Sätze Betriebsanweisung:

  R23/25:Giftig beim Einatmen und Verschlucken.
  R33:Gefahr kumulativer Wirkungen.

• S-Sätze Betriebsanweisung:

  S45:Bei Unfall oder Unwohlsein sofort Arzt zuziehen (wenn möglich, dieses Etikett vorzeigen).

• Beschreibung

  Digitoxin is the most powerful and reliable of the glucosides which have been extracted from digitalis leave. It is a cardiac glycoside (CG). It is a cardiotonic drug, which exhibits cardiac and anti-cancer properties. Digitoxin inhibits nuclear factor kappa B (NF-κB) signaling. It is used to treat congestive heart failure and cardiac arrhythmia. Digitoxin prevents microtubule formation.

• Beschreibung

  Digitoxin is a cardiac glycoside that has been found in Digitalis and has diverse biological activities. It inhibits human recombinant α₁β₁, α₂β₂, and α₃β₁ subunit-containing Na⁺/K⁺-ATPases with K_i values of 250, 63, and 136 nM, respectively. Digitoxin inhibits the human-ether-a-go-go (hERG) potassium channel, also known as K_v11.1, in HEK293 cells expressing hERG (IC₅₀ = 11.1 nM). It enhances developed tension and contractile force in electrically stimulated isolated guinea pig left atrial muscle when used at concentrations of 0.2 and 0.4 μM, respectively. Dietary administration of digitoxin (~1 mg/kg per day) attenuates congestive heart failure and reduces myocardial hypertrophy in a rat model of myocardial infarction induced by coronary artery ligation. Digitoxin is also cytotoxic to a panel of 10 human cancer cell lines, including myeloma, lymphoma, and leukemia cancer cells, with IC₅₀ values ranging from 12 to 76 nM. Formulations containing digitoxin have previously been used in the treatment of congestive heart failure and cardiac arrhythmias.

• Chemische Eigenschaften

  White Solid

• Originator

  Crystodigin,Lilly

• Verwenden

  Digitoxin is used for chronic cardiac insufficiency, tachyarrhythmia form of atrial fibrillation, paroxysmal ciliary arrhythmia, and paroxysmal supraventricular tachycaria.

• Verwenden

  Digitoxin has been used as a labeled drugs for binding sites on human serum albumin (HSA). It has also been used to test its anti-transmissible gastroenteritis virus (TGEV) activity.

• Indications

  Digitoxin (Dig) is an FDA approved drug for the treatment of cardiac disease.
  Digitoxin is used for the treatment of heart failure, especially in people with impaired kidney function. It is also used to treat certain kinds of heart arrhythmia, such as atrial fibrillation.
  Digoxin is used to treat heart failure and abnormal heart rhythms (arrhythmias). It also helps the heart work better and control heart rate. Digoxin may be used after a heart attack. This medication comes in various forms: tablet, capsule, or pediatric elixir (liquid). It is available under the brand names Lanoxin, Cardoxin, Digitek, Digox, and Lanoxicaps.

• Definition

  ChEBI: Digitoxin is a cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain. It has a role as an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is functionally related to a digitoxigenin. It is a conjugate acid of a digitoxin(1-).

• Manufacturing Process

  1000 g of Digitalis purpurea leaves were moistened thoroughly with a menstruum consisting of 60% ethyl alcohol and 40% water and were packed in a percolator with enough of the menstruum to leave a stratum above the drug. After maceration overnight, the drug was percolated with about 7 liters of the 60%-alcohol menstruum and about 5 liters of percolate or extract were collected. 400 g of solid lead acetate were added to the percolate and the mixture was stirred until all the lead acetate had dissolved. After standing for at least one hour, the copious light green precipitate was centrifuged off and washed successively with 1000 ml and 500 ml portions of 60% alcohol. The washings were combined with the filtrate from the centrifuge and most of the excess lead acetate removed by treatment with a saturated solution of sodium carbonate monohydrate. The resulting lead carbonate was filtered off, washed with two 200 ml portions of 60% ethyl alcohol, and the washings combined with the filtrate. Hydrogen sulfide was then passed through the combined liquids until no more lead sulfide precipitated. The filtrate and washings resulting from filtering off the lead sulfide were concentrated in vacuo at or below 40°C to a volume of 2000 ml and saturated with a salt, such as sodium chloride, to facilitate subsequent extraction with a water-immiscible organic solvent. The mixture was extracted five times with 600 ml of a solvent consisting of two volumes of chloroform and three volumes of amyl ether. The chloroform-amyl ether solution is extracted with about four 400 ml portions of a 10% solution of sodium carbonate monohydrate to remove any gitalin that may have carried through in the process and vegetative extractive material. After drying over anhydrous sodium sulfate and filtering, the chloroform-amyl ether solution was concentrated in vacuo at 75°-85°C to a volume of about 25 ml. After cooling to room temperature, the concentrate was mixed with about four volumes of petroleum ether and allowed to stand for about one hour at room temperature. The dark colored, amorphous precipitate was filtered and washed with petroleum ether to ensure that all fat had been removed. The precipitate was dissolved in 100 ml of dilute alcohol (1:1) and the slight precipitate remaining after thorough agitation was filtered off. The filtrate was made slightly alkaline with 10% ammonia water and 10 g of solid lead acetate were dissolved therein with agitation. The light brown precipitate, which formed, was centrifuged off and washed with two 50 ml portions of dilute alcohol. Excess lead acetate was removed by passage of hydrogen sulfide through the solution until no more lead sulfide precipitated. The filtrate and washings resulting from removal of the lead sulfide was concentrated below 40°C. After making slightly alkaline with ammonia water, the concentrate was extracted with three 50 ml portions of chloroform. The chloroform extract of digitoxin was dried over anhydrous sodium sulfate. After filtering and washing the filter with dry chloroform, the chloroform extract was heated on a water bath to remove the chloroform and the residue was dissolved in 20ml of hot alcohol at about 60°C., and diluted with hot distilled water at 60°C to an alcohol concentration of 30%. Upon standing overnight, the digitoxin settled out as a yellowish orange, mostly amorphous solid together with some needle and rosette crystals.
  The digitoxin was filtered off, and dried in a vacuum desiccator over calcium chloride and then was dissolved In 10 cc. of dry chloroform after which 15 ml of dry amyl ether was added, followed by 100 ml of petroleum ether. After standing one hour, the precipitate was filtered off, washed with petroleum ether, and dried in a vacuum desiccator until all traces of amyl ether were removed. One 1ml of alcohol for each 25 milligrams of material was added to the dried precipitate and the mixture was heated on a water-bath at 60°C until the precipitate had comp

• Trademarks

  Crystodigin (Lilly) .

• Therapeutic Function

  Cardiotonic, Topical venotonic

• Allgemeine Beschreibung

  Odorless white or pale buff microcrystalline powder. Used as a cardiotonic drug.

• Health Hazard

  Material is bioactive and capable of causing cardiac arrythmias and electrolyte imbalances that may be fatal. Death is due to ventricular fibrillation or cardiac standstill. Material has a high toxicity hazard rating; it may cause death or permanent injury after a very short exposure. It is classified as super toxic; an estimated single lethal dose is 3-10 mg.

• Brandgefahr

  When heated to decomposition, DIGITOXIN emits acrid smoke and irritating fumes.

• Sicherheitsprofil

  A deadly poison by most routes. Human systemic effects: arrhythmias, cardiomyopathy, EKG changes, nausea or vomiting, paresthesia, pulse rate increase, thrombocytopenia. Human reproductive effects by ingestion: reduced viability of newborn. An eye irritant. When heated to decomposition it emits acrid smoke and irritating fumes. See also DIGITALIS.

• mögliche Exposition

  NaturalProduct; Reproductive Effector; Primary Irritant. This material is used as a cardiotonic drug. Digitoxin is the most toxiccomponent of digitalis.

• Erste Hilfe

  If this chemical gets into the eyes, remove anycontact lenses at once and irrigate immediately for at least15 min, occasionally lifting upper and lower lids. Seek medical attention immediately. If this chemical contacts theskin, remove contaminated clothing and wash immediatelywith soap and water. Seek medical attention immediately. Ifthis chemical has been inhaled, remove from exposure,begin rescue breathing (using universal precautions, including resuscitation mask) if breathing has stopped and CPR ifheart action has stopped. Transfer promptly to a medicalfacility. When this chemical has been swallowed, get medical attention. Give large quantities of water and inducevomiting. Do not make an unconscious person vomit.

• Lager

  Color Code—Blue: Health Hazard/Poison: Storein a secure poison location. Prior to working with digitoxinyou should be trained on its proper handling and storage.Store in tightly closed containers in a refrigerator.

• Versand/Shipping

  This compound can be classed under Medicine,solid, toxic, n.o.s. It requires a shipping label of“POISONOUS/TOXIC MATERIALS.” It falls in HazardClass 6.1 and Packing Group III.

• läuterung methode

  Digitoxin crystallises from MeOH, aqueous EtOH with 0.5 to 1 H2O and from H2O as the dihydrate. It also crystallises from CHCl3/Et2O as anhydrous crystals. The hydrate dehydrates at 120o/vacuum. Its solubility is 2.5% in CHCl3, 1.7% in EtOH, 0.25% in EtOAc, and 0.001% in H2O; and has E1cm 202.5 at 219-220nm (50% EtOH). [Stoll et al. Helv Chim Acta 37 1134 1954, Demoen & Janssen J Am Pharm Assoc 42 635 1953, Beilstein 18 IV 1478.]

• Mode of action

  Digitoxin is a purified cardiac glycoside similar in structure and function to Digoxin. Unlike Digoxin, Digitoxin is eliminated from the body via the liver and not the kidneys. Both drugs are used to treat various heart conditions. Cardiac glycosides bind to a site on the extracellular aspect of the a-subunit of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. Digitoxin inhibits the sodium-potassium ATPase in heart muscle cells, resulting in increased force of contractions (positive inotropic), reduced speed of electric conduction (negative dromotropic), increased excitability (positive bathmotropic), and reduced frequency of heartbeat (negative chronotropic).

Digitoxin Upstream-Materialien And Downstream Produkte

Digitoxin Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global(222)Suppliers

71-63-6, Digitoxin Verwandte Suche: